secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K
Filed at:   2022-06-15T23:59:59+00:00
Accession:  0001140361-22-023001
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022
-----------------------------------------------------------------------

- Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.
- Kappa's FY2022 forecast revenues ~NOK 500M (~$53M) with strong growth and margin profile.
- Additional earn-out potential of 0% to 16% of enterprise value in 2024 based on performance.
- Closing expected Q2 2022; financed via existing revolver and cash on hand.
- Deal expected to be accretive to Balchem's adjusted EPS in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/0001140361-22-023001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/brhc10038776_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-023001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer